Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer.
Mitsuhiko Iwamoto
No relevant relationships to disclose
Nayuko Sato
No relevant relationships to disclose
Risa Terasawa
No relevant relationships to disclose
Hiroya Fujioka
No relevant relationships to disclose
Yuko Takahashi
No relevant relationships to disclose
Kosei Kimura
No relevant relationships to disclose
Satoru Tanaka
No relevant relationships to disclose
Kazuhisa Uchiyama
No relevant relationships to disclose